Mariner LLC raised its position in shares of Fresenius Medical Care AG (NYSE:FMS - Free Report) by 29.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 52,552 shares of the company's stock after purchasing an additional 11,871 shares during the period. Mariner LLC's holdings in Fresenius Medical Care were worth $1,190,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also made changes to their positions in FMS. Callan Family Office LLC purchased a new position in Fresenius Medical Care during the fourth quarter valued at approximately $502,000. Raymond James Financial Inc. purchased a new stake in shares of Fresenius Medical Care during the 4th quarter worth $405,000. Callan Capital LLC purchased a new stake in shares of Fresenius Medical Care during the fourth quarter valued at about $297,000. Sanctuary Advisors LLC acquired a new stake in Fresenius Medical Care in the fourth quarter valued at approximately $983,000. Finally, ABC Arbitrage SA acquired a new position in shares of Fresenius Medical Care during the fourth quarter worth $4,215,000. 8.37% of the stock is currently owned by hedge funds and other institutional investors.
Fresenius Medical Care Stock Performance
Shares of NYSE:FMS traded up $0.71 on Friday, hitting $25.73. 328,717 shares of the company were exchanged, compared to its average volume of 317,005. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The stock's 50 day moving average price is $24.11 and its 200 day moving average price is $23.14. Fresenius Medical Care AG has a 1-year low of $17.93 and a 1-year high of $26.04. The firm has a market capitalization of $15.10 billion, a P/E ratio of 21.30, a price-to-earnings-growth ratio of 0.76 and a beta of 0.93.
Wall Street Analyst Weigh In
Several research analysts recently weighed in on the company. Truist Financial boosted their target price on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a "hold" rating in a research note on Monday, January 6th. StockNews.com upgraded Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th.
View Our Latest Report on FMS
Fresenius Medical Care Company Profile
(
Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
See Also
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
